Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human mitochondrial DNA diseases.

T Pulkes1, M G Hanna

  • 1Muscle and Neurogenetics Sections, University Department of Clinical Neurology, Institute of Neurology, University College London, Queen Square, WC1N 3BG, London, UK.

Advanced Drug Delivery Reviews
|May 30, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Excitability properties of mouse and human skeletal muscle fibres compared by muscle velocity recovery cycles.

Neuromuscular disorders : NMD·2022
Same author

Clinical and genetic spectrum of a Chinese cohort with SCN4A gene mutations.

Neuromuscular disorders : NMD·2021
Same author

Urogenital symptoms in mitochondrial disease: overlooked and undertreated.

European journal of neurology·2019
Same author

A key to the backdoor into the castle: The clinical ramifications of immunoediting driven by antigenic competition.

Human vaccines & immunotherapeutics·2017
Same author

Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.

Annals of the rheumatic diseases·2017
Same author

Lord Walton of Detchant - obituary.

European journal of neurology·2016
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

Mitochondrial encephalomyopathies, often caused by mitochondrial DNA mutations, present diverse symptoms with no cure. This study classifies common mutations, offering insights for potential therapeutic strategies.

Area of Science:

  • Genetics
  • Molecular Biology
  • Neurology

Background:

  • Mitochondrial encephalomyopathies are a diverse group of disorders linked to faulty oxidative phosphorylation.
  • These conditions lead to significant patient morbidity and mortality, with no current cure.
  • Most genetically defined cases stem from mutations in mitochondrial DNA (mtDNA).

Purpose of the Study:

  • To elucidate the key features of mitochondrial DNA genetics.
  • To outline common disease phenotypes associated with mtDNA defects.
  • To propose a classification of pathogenic mtDNA point mutations for therapeutic consideration.

Main Methods:

  • Review of existing literature on mitochondrial DNA genetics.
  • Analysis of genotype-phenotype correlations in mitochondrial diseases.

Related Experiment Videos

  • Development of a classification system for mtDNA point mutations.

    • Main Results:

    • Detailed description of fundamental mitochondrial DNA genetic principles.
    • Identification and categorization of prevalent clinical presentations linked to mtDNA abnormalities.
    • A structured classification of pathogenic mtDNA point mutations is presented.

    Conclusions:

    • Understanding mtDNA genetics is crucial for comprehending mitochondrial encephalomyopathies.
    • The proposed classification may guide future therapeutic interventions.
    • Further research into genotype-phenotype relationships is warranted for improved patient outcomes.